On October 9, 2026, a clinical trial involving nesiritide was registered under the title "Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients." The trial, identified as NCT07869329, is listed with a phase of not applicable. Its current status is not yet recruiting, meaning participant enrollment has not begun as of the date recorded.
Nesiritide remains classified as an unapproved research compound. This trial update reflects only the registration details available, including the study title, phase designation, and recruitment status. No outcomes, results, or efficacy data have been reported as part of this update.
The trial's listed purpose concerns biomarker testing related to radiation-associated heart disease in patients with lung cancer, as stated in its title. No further details about methodology, patient criteria, or endpoints are included in this update. As the trial has not yet begun recruiting, no interim or final data are currently available for review.
Readers seeking additional background on nesiritide, including its research history and regulatory status, can consult the compound overview for further context.